GeronGERN
GERN
About: Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
Employees: 229
0
Funds holding %
of 7,431 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
41% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 69
31% more call options, than puts
Call options by funds: $1.13M | Put options by funds: $861K
0.46% more ownership
Funds ownership: 80.03% [Q1] → 80.49% (+0.46%) [Q2]
7% less funds holding
Funds holding: 269 [Q1] → 250 (-19) [Q2]
11% less capital invested
Capital invested by funds: $812M [Q1] → $723M (-$88.4M) [Q2]
33% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 40
33% less funds holding in top 10
Funds holding in top 10: 3 [Q1] → 2 (-1) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$1
30%
downside
Avg. target
$1
30%
downside
High target
$1
30%
downside
1 analyst rating
0 positive
0%
0 neutral
0%
1 negative
100%
Goldman Sachs Corinne Jenkins | 30%downside $1 | Sell Reinstated | 10 Jul 2025 |
Financial journalist opinion
Based on 11 articles about GERN published over the past 30 days
Neutral
Business Wire
1 week ago
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 522,000 shares of its common stock, consisting of stock options to purchase an aggregate of 348,000 shares of common stock, and restricted stock units (“RSUs”) representing an aggregate of 174,000 shares of common stock, to eleven newly hired employees as an inducement material to their acceptance of emplo.
Neutral
GlobeNewsWire
1 week ago
Geron Corporation Investors: Company Investigated by the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses
Neutral
GlobeNewsWire
1 week ago
GERON (GERN) ALERT: Bragar Eagel & Squire, P.C. is Investigating Geron Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Geron Corporation (NASDAQ: GERN) on behalf of long-term stockholders following a class action complaint that was filed against Geron on March 14, 2025 with a Class Period from February 28, 2024 to February 25, 2025. Our investigation concerns whether the board of directors of Geron have breached their fiduciary duties to the company.
Neutral
Business Wire
2 weeks ago
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted an equity award in the form of stock options to purchase 11,000,000 shares of common stock to Harout Semerjian, Geron's new President and Chief Executive Officer, as an inducement material to his acceptance of employment with Geron. The stock options were granted on August 7, 2025. The stock options have an exercise price of $1.30 per share, wh.
Negative
Seeking Alpha
2 weeks ago
Geron: I Think We've Seen This Movie Before
Geron's Q2'25 sales of Rytelo (imetelstat) show clear growth, with net product revenue rising to $49M and underlying demand up 17%. Recent performance dispels fears that Rytelo's market share has already peaked, echoing past misjudgments seen with AUPH. A run-up into an interim readout from IMpactMF, GERN's trial of imetelstat in myelofibrosis, could begin in H1'26, since results are expected in H2'26.
Neutral
Seeking Alpha
2 weeks ago
Geron Corporation (GERN) Q2 2025 Earnings Call Transcript
Geron Corporation (NASDAQ:GERN ) Q2 2025 Earnings Conference Call August 6, 2025 8:00 AM ET Company Participants & - Corporate Participant David Borah - Corporate Participant Dawn Carter Bir - Interim President & Chief Executive Officer and Director Harout Semerjian - Corporate Participant James Ziegler - Executive VP & Chief Commercial Officer Joseph Emile Eid - Executive Vice President of Research Development Michelle J. Robertson - Executive VP, CFO, Treasurer and Principal Financial & Accounting Officer Conference Call Participants Corinne Johnson - Goldman Sachs Group, Inc., Research Division Emily Claudia Bodnar - H.C.
Positive
The Motley Fool
2 weeks ago
Geron (GERN) Q2 Revenue Jumps 5,477%
Geron (GERN) Q2 Revenue Jumps 5,477%
Negative
Zacks Investment Research
2 weeks ago
Geron (GERN) Reports Q2 Loss, Tops Revenue Estimates
Geron (GERN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.1 per share a year ago.
Neutral
Business Wire
2 weeks ago
Geron Corporation Reports Second Quarter 2025 Financial Results and Recent Business Highlights
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the second quarter of 2025 and recent business highlights. In a separate press release today, the Company announced the appointment of Harout Semerjian as incoming President and CEO. "We are pleased that our sharpened sales strategy is demonstrating signs of commercial success as e.
Neutral
Business Wire
2 weeks ago
Geron Appoints Harout Semerjian as President and Chief Executive Officer
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Harout Semerjian as President and Chief Executive Officer (CEO) and a member of the Board of Directors, effective tomorrow. Mr. Semerjian will succeed Dawn Carter Bir, who has served as Interim President and CEO since March 2025. Ms. Bir will continue in her role on Geron's Board of.
Charts implemented using Lightweight Charts™